Does the media favor BDX or PODD?

In the previous week, Insulet had 16 more articles in the media than Becton, Dickinson and Company. MarketBeat recorded 44 mentions for Insulet and 28 mentions for Becton, Dickinson and Company. Becton, Dickinson and Company's average media sentiment score of 1.19 beat Insulet's score of 0.46 indicating that Becton, Dickinson and Company is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Becton, Dickinson and Company 18 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Insulet 14 Very Positive mention(s) 2 Positive mention(s) 27 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, PODD or IDXX?

IDEXX Laboratories has higher revenue and earnings than Insulet. Insulet is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insulet $2.71B 4.23 $247.10M $4.30 38.45 IDEXX Laboratories $4.30B 10.25 $1.06B $13.58 41.17

Does the media prefer PODD or IDXX?

In the previous week, Insulet had 23 more articles in the media than IDEXX Laboratories. MarketBeat recorded 44 mentions for Insulet and 21 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 1.37 beat Insulet's score of 0.46 indicating that IDEXX Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insulet 14 Very Positive mention(s) 2 Positive mention(s) 27 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IDEXX Laboratories 15 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, PODD or RMD?

ResMed has higher revenue and earnings than Insulet. ResMed is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insulet $2.71B 4.23 $247.10M $4.30 38.45 ResMed $5.15B 5.96 $1.40B $10.37 20.38

Is PODD or RMD more profitable?

ResMed has a net margin of 27.44% compared to Insulet's net margin of 10.44%. Insulet's return on equity of 26.87% beat ResMed's return on equity. Company Net Margins Return on Equity Return on Assets Insulet 10.44% 26.87% 12.01% ResMed 27.44% 25.35% 18.69%

Does the media prefer PODD or RMD?

In the previous week, Insulet had 30 more articles in the media than ResMed. MarketBeat recorded 44 mentions for Insulet and 14 mentions for ResMed. ResMed's average media sentiment score of 1.20 beat Insulet's score of 0.46 indicating that ResMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insulet 14 Very Positive mention(s) 2 Positive mention(s) 27 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ResMed 10 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, PODD or DXCM?

DexCom has higher revenue and earnings than Insulet. DexCom is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insulet $2.71B 4.23 $247.10M $4.30 38.45 DexCom $4.66B 6.75 $836.30M $2.53 32.98

Is PODD or DXCM more profitable?

DexCom has a net margin of 20.12% compared to Insulet's net margin of 10.44%. DexCom's return on equity of 35.94% beat Insulet's return on equity. Company Net Margins Return on Equity Return on Assets Insulet 10.44% 26.87% 12.01% DexCom 20.12% 35.94% 14.75%

Does the media refer more to PODD or DXCM?

In the previous week, DexCom had 9 more articles in the media than Insulet. MarketBeat recorded 53 mentions for DexCom and 44 mentions for Insulet. DexCom's average media sentiment score of 0.92 beat Insulet's score of 0.46 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insulet 14 Very Positive mention(s) 2 Positive mention(s) 27 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral DexCom 22 Very Positive mention(s) 4 Positive mention(s) 18 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, PODD or STE?

STERIS has higher revenue and earnings than Insulet. STERIS is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insulet $2.71B 4.23 $247.10M $4.30 38.45 STERIS $5.94B 3.76 $782.30M $7.93 28.85

Is PODD or STE more profitable?

STERIS has a net margin of 13.18% compared to Insulet's net margin of 10.44%. Insulet's return on equity of 26.87% beat STERIS's return on equity. Company Net Margins Return on Equity Return on Assets Insulet 10.44% 26.87% 12.01% STERIS 13.18% 14.15% 9.52%

Does the media refer more to PODD or STE?

In the previous week, Insulet had 24 more articles in the media than STERIS. MarketBeat recorded 44 mentions for Insulet and 20 mentions for STERIS. STERIS's average media sentiment score of 1.02 beat Insulet's score of 0.46 indicating that STERIS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insulet 14 Very Positive mention(s) 2 Positive mention(s) 27 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral STERIS 9 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Insulet (PODD) Competitors

$165.35 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$165.50 +0.15 (+0.09%)

As of 07/31/2026 07:34 PM Eastern

Compare

PODD vs. BDX, IDXX, RMD, DXCM, and STE

Should you buy Insulet stock or one of its competitors? MarketBeat compares Insulet with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Insulet include Becton, Dickinson and Company (BDX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), and STERIS (STE).

How does Insulet compare to Becton, Dickinson and Company?

Becton, Dickinson and Company (NYSE:BDX) and Insulet (NASDAQ:PODD) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

In the previous week, Insulet had 16 more articles in the media than Becton, Dickinson and Company. MarketBeat recorded 44 mentions for Insulet and 28 mentions for Becton, Dickinson and Company. Becton, Dickinson and Company's average media sentiment score of 1.19 beat Insulet's score of 0.46 indicating that Becton, Dickinson and Company is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Becton, Dickinson and Company	18 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Insulet	14 Very Positive mention(s)	2 Positive mention(s)	27 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Becton, Dickinson and Company presently has a consensus target price of $180.93, suggesting a potential upside of 8.87%. Insulet has a consensus target price of $233.38, suggesting a potential upside of 41.14%. Given Insulet's stronger consensus rating and higher possible upside, analysts plainly believe Insulet is more favorable than Becton, Dickinson and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Becton, Dickinson and Company	1 Sell rating(s)	8 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.41
Insulet	2 Sell rating(s)	5 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.68

Becton, Dickinson and Company has higher revenue and earnings than Insulet. Insulet is trading at a lower price-to-earnings ratio than Becton, Dickinson and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Becton, Dickinson and Company	$21.84B	2.10	$1.68B	$3.95	42.07
Insulet	$2.71B	4.23	$247.10M	$4.30	38.45

Insulet has a net margin of 10.44% compared to Becton, Dickinson and Company's net margin of 5.33%. Insulet's return on equity of 26.87% beat Becton, Dickinson and Company's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Becton, Dickinson and Company	5.33%	15.37%	7.11%
Insulet	10.44%	26.87%	12.01%

87.0% of Becton, Dickinson and Company shares are owned by institutional investors. 0.4% of Becton, Dickinson and Company shares are owned by insiders. Comparatively, 0.4% of Insulet shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Becton, Dickinson and Company has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market. Comparatively, Insulet has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market.

Summary

Insulet beats Becton, Dickinson and Company on 10 of the 16 factors compared between the two stocks.

How does Insulet compare to IDEXX Laboratories?

Insulet (NASDAQ:PODD) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

87.8% of IDEXX Laboratories shares are owned by institutional investors. 0.4% of Insulet shares are owned by company insiders. Comparatively, 0.8% of IDEXX Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Insulet had 23 more articles in the media than IDEXX Laboratories. MarketBeat recorded 44 mentions for Insulet and 21 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 1.37 beat Insulet's score of 0.46 indicating that IDEXX Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insulet	14 Very Positive mention(s)	2 Positive mention(s)	27 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IDEXX Laboratories	15 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Insulet presently has a consensus target price of $233.38, suggesting a potential upside of 41.14%. IDEXX Laboratories has a consensus target price of $749.00, suggesting a potential upside of 33.97%. Given Insulet's stronger consensus rating and higher possible upside, equities analysts clearly believe Insulet is more favorable than IDEXX Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	2 Sell rating(s)	5 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.68
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60

Insulet has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market. Comparatively, IDEXX Laboratories has a beta of 1.54, meaning that its share price is 54% more volatile than the broader market.

IDEXX Laboratories has higher revenue and earnings than Insulet. Insulet is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$2.71B	4.23	$247.10M	$4.30	38.45
IDEXX Laboratories	$4.30B	10.25	$1.06B	$13.58	41.17

IDEXX Laboratories has a net margin of 24.63% compared to Insulet's net margin of 10.44%. IDEXX Laboratories' return on equity of 70.87% beat Insulet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insulet	10.44%	26.87%	12.01%
IDEXX Laboratories	24.63%	70.87%	32.56%

Summary

IDEXX Laboratories beats Insulet on 12 of the 16 factors compared between the two stocks.

How does Insulet compare to ResMed?

Insulet (NASDAQ:PODD) and ResMed (NYSE:RMD) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, Insulet had 30 more articles in the media than ResMed. MarketBeat recorded 44 mentions for Insulet and 14 mentions for ResMed. ResMed's average media sentiment score of 1.20 beat Insulet's score of 0.46 indicating that ResMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insulet	14 Very Positive mention(s)	2 Positive mention(s)	27 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ResMed	10 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ResMed has higher revenue and earnings than Insulet. ResMed is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$2.71B	4.23	$247.10M	$4.30	38.45
ResMed	$5.15B	5.96	$1.40B	$10.37	20.38

Insulet has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market. Comparatively, ResMed has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

ResMed has a net margin of 27.44% compared to Insulet's net margin of 10.44%. Insulet's return on equity of 26.87% beat ResMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insulet	10.44%	26.87%	12.01%
ResMed	27.44%	25.35%	18.69%

Insulet presently has a consensus price target of $233.38, suggesting a potential upside of 41.14%. ResMed has a consensus price target of $246.25, suggesting a potential upside of 16.49%. Given Insulet's stronger consensus rating and higher probable upside, equities analysts clearly believe Insulet is more favorable than ResMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	2 Sell rating(s)	5 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.68
ResMed	0 Sell rating(s)	9 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.44

55.0% of ResMed shares are held by institutional investors. 0.4% of Insulet shares are held by insiders. Comparatively, 0.7% of ResMed shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

ResMed beats Insulet on 9 of the 16 factors compared between the two stocks.

How does Insulet compare to DexCom?

Insulet (NASDAQ:PODD) and DexCom (NASDAQ:DXCM) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

97.8% of DexCom shares are held by institutional investors. 0.4% of Insulet shares are held by insiders. Comparatively, 0.3% of DexCom shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Insulet presently has a consensus price target of $233.38, suggesting a potential upside of 41.14%. DexCom has a consensus price target of $88.13, suggesting a potential upside of 5.60%. Given Insulet's higher possible upside, equities analysts plainly believe Insulet is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	2 Sell rating(s)	5 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.68
DexCom	1 Sell rating(s)	3 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.89

DexCom has higher revenue and earnings than Insulet. DexCom is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$2.71B	4.23	$247.10M	$4.30	38.45
DexCom	$4.66B	6.75	$836.30M	$2.53	32.98

DexCom has a net margin of 20.12% compared to Insulet's net margin of 10.44%. DexCom's return on equity of 35.94% beat Insulet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insulet	10.44%	26.87%	12.01%
DexCom	20.12%	35.94%	14.75%

Insulet has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, DexCom has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market.

In the previous week, DexCom had 9 more articles in the media than Insulet. MarketBeat recorded 53 mentions for DexCom and 44 mentions for Insulet. DexCom's average media sentiment score of 0.92 beat Insulet's score of 0.46 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insulet	14 Very Positive mention(s)	2 Positive mention(s)	27 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DexCom	22 Very Positive mention(s)	4 Positive mention(s)	18 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

DexCom beats Insulet on 12 of the 16 factors compared between the two stocks.

How does Insulet compare to STERIS?

Insulet (NASDAQ:PODD) and STERIS (NYSE:STE) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

STERIS has a net margin of 13.18% compared to Insulet's net margin of 10.44%. Insulet's return on equity of 26.87% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insulet	10.44%	26.87%	12.01%
STERIS	13.18%	14.15%	9.52%

STERIS has higher revenue and earnings than Insulet. STERIS is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$2.71B	4.23	$247.10M	$4.30	38.45
STERIS	$5.94B	3.76	$782.30M	$7.93	28.85

94.7% of STERIS shares are held by institutional investors. 0.4% of Insulet shares are held by company insiders. Comparatively, 1.1% of STERIS shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Insulet presently has a consensus price target of $233.38, indicating a potential upside of 41.14%. STERIS has a consensus price target of $277.25, indicating a potential upside of 21.20%. Given Insulet's higher probable upside, equities research analysts clearly believe Insulet is more favorable than STERIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	2 Sell rating(s)	5 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.68
STERIS	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Insulet had 24 more articles in the media than STERIS. MarketBeat recorded 44 mentions for Insulet and 20 mentions for STERIS. STERIS's average media sentiment score of 1.02 beat Insulet's score of 0.46 indicating that STERIS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insulet	14 Very Positive mention(s)	2 Positive mention(s)	27 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
STERIS	9 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Insulet has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market. Comparatively, STERIS has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market.

Summary

Insulet and STERIS tied by winning 8 of the 16 factors compared between the two stocks.

Get Insulet News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PODD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PODD vs. The Competition

Export

Metric	Insulet	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$11.45B	$5.58B	$6.86B	$12.42B
Dividend Yield	N/A	1.79%	2.59%	10.03%
P/E Ratio	38.45	23.11	282.27	24.66
Price / Sales	4.23	56.61	581.52	86.64
Price / Cash	26.15	32.53	28.60	46.71
Price / Book	7.68	6.29	10.93	6.07
Net Income	$247.10M	$151.15M	$3.49B	$347.99M
7 Day Performance	0.21%	1.01%	-0.64%	-0.42%
1 Month Performance	0.53%	4.43%	-3.78%	-4.80%
1 Year Performance	-41.96%	2.35%	61.99%	18.61%

Insulet Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PODD Insulet	4.7133 of 5 stars	$165.35 flat	$233.38 +41.1%	-42.0%	$11.45B	$2.71B	38.45	5,400	Trending News Upcoming Earnings Analyst Upgrade
BDX Becton, Dickinson and Company	4.5294 of 5 stars	$158.94 +1.7%	$180.29 +13.4%	-5.7%	$43.08B	$21.84B	40.24	72,000	Positive News Upcoming Earnings Dividend Announcement
IDXX IDEXX Laboratories	4.151 of 5 stars	$556.20 +2.2%	$749.00 +34.7%	+4.4%	$42.94B	$4.30B	40.96	11,000	Positive News Upcoming Earnings
RMD ResMed	4.7781 of 5 stars	$203.34 +4.1%	$246.25 +21.1%	-24.2%	$28.33B	$5.15B	19.61	10,600	Positive News Upcoming Earnings Gap Down
DXCM DexCom	3.896 of 5 stars	$73.37 +2.6%	$85.36 +16.3%	+5.3%	$27.61B	$4.66B	31.35	11,000	Trending News Earnings Report Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PODD) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Insulet (PODD) Competitors

PODD vs. BDX, IDXX, RMD, DXCM, and STE

How does Insulet compare to Becton, Dickinson and Company?

Summary

How does Insulet compare to IDEXX Laboratories?

Summary

How does Insulet compare to ResMed?

Summary

How does Insulet compare to DexCom?

Summary

How does Insulet compare to STERIS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PODD vs. The Competition

Insulet Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Insulet (PODD) Competitors

PODD vs. BDX, IDXX, RMD, DXCM, and STE

How does Insulet compare to Becton, Dickinson and Company?

Does the media favor BDX or PODD?

Do analysts rate BDX or PODD?

Which has stronger earnings & valuation, BDX or PODD?

Is BDX or PODD more profitable?

Do institutionals & insiders have more ownership in BDX or PODD?

Which has more volatility and risk, BDX or PODD?

Summary

How does Insulet compare to IDEXX Laboratories?

Do insiders and institutionals hold more shares of PODD or IDXX?

Does the media prefer PODD or IDXX?

Do analysts recommend PODD or IDXX?

Which has more risk and volatility, PODD or IDXX?

Which has stronger valuation and earnings, PODD or IDXX?

Is PODD or IDXX more profitable?

Summary

How does Insulet compare to ResMed?

Does the media prefer PODD or RMD?

Which has stronger earnings and valuation, PODD or RMD?

Which has more volatility & risk, PODD or RMD?

Is PODD or RMD more profitable?

Do analysts prefer PODD or RMD?

Do insiders & institutionals have more ownership in PODD or RMD?

Summary

How does Insulet compare to DexCom?

Do institutionals & insiders have more ownership in PODD or DXCM?

Do analysts recommend PODD or DXCM?

Which has higher earnings and valuation, PODD or DXCM?

Is PODD or DXCM more profitable?

Which has more risk and volatility, PODD or DXCM?

Does the media refer more to PODD or DXCM?

Summary

How does Insulet compare to STERIS?

Is PODD or STE more profitable?

Which has higher valuation and earnings, PODD or STE?

Do insiders and institutionals hold more shares of PODD or STE?

Do analysts rate PODD or STE?

Does the media refer more to PODD or STE?

Which has more risk and volatility, PODD or STE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PODD vs. The Competition

Insulet Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools